Gynaecological cancers are categorised as 'rare' diseases, although collectively they affect over 16,000 women each year in the UK alone. There is a lack of real understanding of these conditions compared with other malignancies, possibly owing to their relative rarity when viewed as individual diseases. The 60th RCOG Study Group brought together a range of experts to examine as many biological aspects of gynaecological cancers as possible, including both surgical and non-surgical therapies. This book presents the findings of the Study Group, with contents including: ¿ current understanding of…mehr
Gynaecological cancers are categorised as 'rare' diseases, although collectively they affect over 16,000 women each year in the UK alone. There is a lack of real understanding of these conditions compared with other malignancies, possibly owing to their relative rarity when viewed as individual diseases. The 60th RCOG Study Group brought together a range of experts to examine as many biological aspects of gynaecological cancers as possible, including both surgical and non-surgical therapies. This book presents the findings of the Study Group, with contents including: ¿ current understanding of the biology of gynaecological cancers ¿ translation of biology to the clinic ¿ state of the art in imaging and therapy ¿ current clinical trials ¿ advances in multimodal therapy ¿ individualised treatment.
Part I. Biology of Gynaecological Cancers: Our Current Understanding: 1. Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for targeting genetic changes in endometrial cancer Susana Banerjee; 3. Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4. Predictive biology of ovarian cancer Christine A. Parkinson and James D. Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of BRCA1 and BRCA2 genes and implications for cancer management Timothy A. Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10. Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish; 12. Endometrial cancer: what have the clinical trials taught us? Andrew Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14. Functional imaging: from tumour biology to the clinic Nandita M. deSouza, Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus Views: 18. Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and Therapeutics; Index.
Part I. Biology of Gynaecological Cancers: Our Current Understanding: 1. Morphological sub-types of ovarian carcinoma: new developments and pathogenesis W. Glenn McCluggage; 2. Novel treatment strategies for targeting genetic changes in endometrial cancer Susana Banerjee; 3. Epigenetic biomarkers in ovarian cancer Robert Brown and Janet Graham; 4. Predictive biology of ovarian cancer Christine A. Parkinson and James D. Brenton; Part II. The Translation of Biology to the Clinic: 5. Biology of BRCA1 and BRCA2 genes and implications for cancer management Timothy A. Yap, Yvette Drew and Susan Shanley; 6. Implications of homologous recombination defectiveness in ovarian cancer Richard J. Edmondson, Asima Mukhopadhyay, Aiste Cerbinskaite and Nicola J. Curtin; 7. The future of PARP inhibitors in the treatment of cancer Yvette Drew, Timothy A. Yap and Stan B. Kaye; Part III. Imaging and Therapy: State of the Art: 8. The role of robotics and the future Tim Mould; 9. 'Ultra-radical' surgery in advanced ovarian cancer Oliver Zivanovic and Dennis S. Chi; 10. Antivascular therapy in gynaecological cancers Leena Mukherjee and Gordon Rustin; 11. Oncolytic viral gene therapy in ovarian cancer Iain A. McNeish; 12. Endometrial cancer: what have the clinical trials taught us? Andrew Clamp; 13. Targeting therapies in cancer: opportunities in ovarian cancer Ahmed Ashour Ahmed, Stefan Knapp, Anil K. Sood and Robert C. Bast Jr; 14. Functional imaging: from tumour biology to the clinic Nandita M. deSouza, Evis Sala, Stavroula Kyriazi and Andrea Rockall; Part IV. What Questions Are Being Asked by Current Clinical Trials?: 15. Current clinical trials in ovarian cancer Christina Fotopoulou, Angus McIndoe, Jalid Sehouli and Hani Gabra; 16. Clinical trials in cervical cancer Karen Tipples and Melanie Powell; 17. Clinical trials in vulval cancer Tito Lopes; Part V. Consensus Views: 18. Consensus views arising from the 60th Study Group: Gynaecological Cancers: Biology and Therapeutics; Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
